Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma

Neeraj Agarwal, MD
Published: Tuesday, Nov 14, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Several new treatment combinations are being tested with checkpoint inhibitors, IDO1 inhibitors, tyrosine kinase inhibitors (TKIs), and VEGFR TKIs, explains Agarwal.

The way patients with newly diagnosed metastatic renal cell carcinoma are treated will be completely different in the next few years, says Agarwal.


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Several new treatment combinations are being tested with checkpoint inhibitors, IDO1 inhibitors, tyrosine kinase inhibitors (TKIs), and VEGFR TKIs, explains Agarwal.

The way patients with newly diagnosed metastatic renal cell carcinoma are treated will be completely different in the next few years, says Agarwal.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x